Why Option Agreements Are the Most Misused Tool in Technology Transfer

Option agreements occupy a strange position in technology transfer. Everyone uses them. Almost no one uses them well.

Photo by Sandeep Verma on Pexels.

The basic idea is sound: a company pays a fee, often modest, sometimes nominal, for the exclusive right to negotiate a license to a piece of university IP within a defined window. It buys time. It signals interest without full commitment. For early-stage technologies where the science is promising but the commercial path isn't yet clear, an option looks like the sensible middle ground between "not interested" and "let's sign a license."

The problem isn't the instrument itself. It's how TTOs and companies have learned to use it, mostly as a way to delay hard conversations rather than resolve them.

The Parking Lot Problem

Here's what actually happens in a significant portion of option deals: a company takes out an option, pays a low four-figure fee, and then does very little for six to twelve months. The clock runs out. They either let it lapse or request an extension, sometimes two or three extensions, before finally walking away or signing a license that looks almost identical to what they could have signed on day one.

Meanwhile, the technology sat. No other companies were approached. The inventor waited. The TTO reported the option as a positive outcome in its pipeline metrics.

This is what I'd call the parking lot problem. An option that isn't tied to concrete due diligence milestones isn't a step toward commercialization, it's a reserved space that keeps everyone else out while the holder decides if they feel like showing up.

What a Well-Structured Option Actually Requires

An option agreement earns its place in the deal when it's built around activity, not just time. That means three things need to be explicit before anyone signs:

1. Defined diligence obligations during the option period. What, specifically, will the company do? Customer discovery interviews? A feasibility study? A prototype build? Vague language like "evaluate commercial potential" is almost useless. Concrete deliverables, a market assessment submitted by month four, a technical report by month eight, give the TTO something to actually track.

2. Option fees that reflect real opportunity cost. A $1,500 option fee on a technology with three other interested parties is effectively a giveaway. Option fees should scale with the exclusivity being granted and the maturity of the technology. For a hot biotech asset with multiple suitors, an option that blocks the field for a year should cost enough that the company has genuine skin in the game.

3. Pre-negotiated license terms. This is the piece most TTOs skip, and it's the one that kills momentum later. If the option converts, what are the royalty rate, the diligence milestones post-license, and the sublicensing terms? Leaving these undefined means the negotiation clock resets to zero the moment the company exercises. That's where deals go to die, not in the option phase, but in the gap between exercise and execution.

graph TD
    A[Option Signed] --> B{Diligence Milestones Met?}
    B -- Yes --> C[Option Exercised]
    B -- No --> D[Option Lapses or Extended]
    C --> E[Pre-negotiated License Executed]
    D --> F[Technology Re-enters Market]
    E --> G[Active Commercialization]

The Inventor Relationship Nobody Accounts For

There's a human cost here that rarely shows up in TTO reports. Inventors watch their technologies get optioned with genuine excitement. When months pass with no visible progress and the option quietly lapses, the effect on their trust in the TTO is corrosive. Many stop filing disclosures. Some pursue startup paths without TTO involvement. A few just conclude that commercialization is theater.

An option that's handled poorly doesn't just waste one deal's time. It damages the relationship with the researcher for years.

What TTOs Should Do Differently

Start treating option agreements as conditional commitments, not exploratory placeholders. Build a short due diligence checklist into every option term sheet before the company signs. Charge fees that create real accountability. And if a company can't articulate what they'll learn during the option period and how they'll decide, that's information, the deal probably isn't ready, and an option won't change that.

The best option agreements I've seen function like a structured pilot: both sides know what success looks like, both sides have obligations, and the path to a full license is visible from the start. That's a tool worth using.

The ones structured as a gentleman's hold on interesting IP? Those mostly just waste time that early-stage technologies don't have to spare.